Tretinoin

Generic Name: Tretinoin

Brand Names: Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈O_₂

CAS Number: 302-79-4

Unique Ingredient Identifier: 5688UTC01R

Background: Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles and activates nuclear receptors to regulate epithelial cell growth and differentiation. Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.

Indication: Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.

Topical tretinoin is also indicated alone or in combination with benzoyl peroxide or clindamycin for the treatment of acne vulgaris. It is also used in prescription and over-the-counter for treating various skin conditions such as melasma, hyperpigmentation, and photoaging alone or in combination with other drugs.

Associated Conditions: Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin

Clinical Trials

Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome

Phase 2

Recruiting

Conditions: Acne Vulgaris

Interventions: Drug: tretinoin 0.025% + Z. officinale patch
Drug: tretinoin 0.025% cream

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-27

Lead Sponsor: Hasanuddin University

Target Recruit Count: 26

Registration Number: NCT06787222

Locations: 🇮🇩
Doctoral Programme, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia

Reverse HER2-negative Immune Resistant Breast Cancer

Phase 2

Recruiting

Conditions: HER2 Negative Breast Cancer

Interventions: Drug: Retinoic Acid
Drug: anti-PD-1 antibody and chemotherapy

First Posted Date: 2024-12-12

Last Posted Date: 2025-05-13

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT06731140

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Phase 3

Recruiting

Conditions: Oropharynx Cancer
Larynx Cancer
Hypopharynx Cancer
Primary Head and Neck Tumor

Interventions: Radiation: Standard radiotherapy
Drug: Vesanoid
Drug: Cisplatin
Radiation: Tailored radiotherapy
Drug: Cetuximab

First Posted Date: 2024-11-26

Last Posted Date: 2025-02-24

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 460

Registration Number: NCT06706401

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Phase 2

Not yet recruiting

Conditions: B-cell Non Hodgkin Lymphoma

Interventions: Drug: All-trans retinoic acid
Drug: zanubrutinib
Radiation: radiotherapy
Drug: CAR-T
Drug: PD-1 inhibitor

First Posted Date: 2024-10-17

Last Posted Date: 2024-11-01

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 35

Registration Number: NCT06646666

Locations: 🇨🇳
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Phase 2

Not yet recruiting

Conditions: Leiomyosarcoma
Sarcoma

Interventions: Drug: all-trans retinoic acid
Drug: Cemiplimab
Procedure: Computed Tomography
Procedure: Magnetic resonance imaging
Procedure: Biospecimen Collection

First Posted Date: 2024-07-30

Last Posted Date: 2025-04-30

Lead Sponsor: Gabriel Tinoco

Target Recruit Count: 16

Registration Number: NCT06528769

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Phase 2

Recruiting

Conditions: Relapsed Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
B-cell Lymphoma

Interventions: Drug: ATRA
Drug: Pembrolizumab

First Posted Date: 2024-07-03

Last Posted Date: 2025-02-03

Lead Sponsor: Rita Assi

Target Recruit Count: 24

Registration Number: NCT06484920

Locations: 🇺🇸
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States